复发缓解型多发性硬化1例并文献学习

doi:10.3969/j.issn.1004-583X.2026.03.009

摘要/Abstract

摘要：

目的探讨复发缓解型多发性硬化的临床特征、诊断及经验分享。方法回顾性分析复发缓解型多发性硬化1例,并复习相关文献。结果患者青年女性,主因左下肢无力16年,加重2月入院,发病前有复发缓解病史,合并银屑病病史,给予甲泼尼龙琥珀酸钠冲击治疗、口服吗替麦考酚酯胶囊等综合治疗后患者病情好转。出院后半年电话随访,患者病情平稳。结论结合病史、症状、体征及影像学检查综合分析、早期诊断是治疗复发缓解型多发性硬化的关键。

关键词: 多发性硬化, 复发缓解型, 生物标志物, 疲劳

Abstract:

Objective To summarize the clinical characteristics, diagnostic approach, and clinical experience in a case of relapsing-remitting multiple sclerosis (RRMS). Methods We retrospectively analyzed one case of RRMS and reviewed the relevant literature. Results The patient was a young female with a 16-year history of left lower-limb weakness, who was admitted after a 2-month aggravation of symptoms. Her history included relapsing-remitting disease activity and comorbid psoriasis. She received intravenous methylprednisolone sodium succinate pulse therapy along with oral mycophenolate mofetil capsules and other comprehensive treatments, after which her condition improved. Telephone follow-up six months after discharge indicated stable clinical status. Conclusion Timely, early diagnosis founded on an integrated assessment of medical history, clinical signs and symptoms, and imaging is crucial for the management of RRMS.

Key words: multiple sclerosis, relapsing-remitting, biomarkers, fatigue

中图分类号:

R744.51

李施雨, 赵维纳. 复发缓解型多发性硬化1例并文献学习[J]. 临床荟萃, 2026, 41(3): 249-253.

Li Shiyu, Zhao Weina. Relapsing-remitting multiple sclerosis: A case report and literature review[J]. Clinical Focus, 2026, 41(3): 249-253.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.03.009

https://www.lchc.cn/CN/Y2026/V41/I3/249

图/表 1

图1 患者头颅、颈椎MRI检查 ①a、b、c、d:头部T1加权成像;② e、f、g、h、i、j、k、l:头部T2加权成像;③m、n、o、p: 头部FLAIR成像; ④q、r、s、t:颈椎T2加权成像;⑤a、e、i、m、q:2019年北京天坛医院头颈MRI;⑥b、f、j、n、r:2022年潍坊医学院头颈MRI;⑦c、g、k、o、s:2023年牡丹江医科大学附属红旗医院头颈MRI;⑧d、h、l、p、t:2025年牡丹江医科大学附属红旗医院头颈MRI。

Fig.1 MRI examination of the patient's head and cervical spine ①a, b, c, d: Head T1-weighted imaging; ②e, f, g, h, i, j, k, l: Head T2-weighted imaging; ③m, n, o, p: Head FLAIR imaging; ④q, r, s, t: Cervical T2-weighted imaging;⑤a, e, i, m, q: Head and neck MRI at Beijing Tiantan Hospital in 2019; ⑥b, f, j, n, r: Head and neck MRI at Weifang Medical University in 2022; ⑦c, g, k, o, s: Head and neck MRI at Hongqi Hospital Affiliated to Mudanjiang Medical University in 2023; ⑧d, h, l, p, t: Head and neck MRI at Hongqi Hospital Affiliated to Mudanjiang Medical University in 2025.

参考文献 20

[1]	Filippi M, Preziosa P, Langdon D, et al. Identifying progression in multiple sclerosis: New perspectives[J]. Ann Neurol, 2020, 88(3):438-452.doi:10.1002/ana.25808.
[2]	Shaw F, Chadwick C. The diagnostic utility of IgG index and oligoclonal bands for multiple sclerosis in a neurology hospital patient population[J]. Ann Clin Biochem, 2023, 60(5):353-355. doi:10.1177/00045632231179618.
[3]	中华医学会放射学分会磁共振学组, 中国医师协会神经内科医师分会. 多发性硬化MRI规范化应用专家共识[J]. 中华放射学杂志, 2023, 57(6):592-599. doi: 10.3760/cma.j.cn112149-20230404-00260.
[4]	Huppke B, Ellenberger D, Hummel H, et al. Association of obesity with multiple sclerosis risk and response to first-line disease modifying drugs in children[J]. JAMA Neurol, 2019, 76(10):1157-1165. doi: 10.1001/jamaneurol.2019.1997.
[5]	Koskderelioglu A, Gedizlioglu M, Eskut N, et al. Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis[J]. Neurol Sci, 2021, 42(6):2471-2479.doi: 10.1007/s10072-020-04847-y. pmid: 33097973
[6]	Huber JE, Chang Y, Meinl I, et al. Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients[J]. J Immunol, 2020, 204(5):1101-1110.doi: 10.4049/jimmunol.1900955. pmid: 32034063
[7]	Sarıdaş F, Özpar R, Özdemir ÜF, et al. Relationship of cranial bone signal intensity to multiple sclerosis clinical course and progression[J]. Sci Prog, 2025, 108(2):368504251336090.doi:10.1177/00368504251336090.
[8]	Perriard G, Mathias A, Enz L, et al. Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes[J]. J Neuroinflammation, 2015, 12:119. doi: 10.1186/s12974-015-0335-3.
[9]	Montague T, Drummond J, Ng K, et al. Advancements in multiple sclerosis[J]. Intern Med J, 2025, 55(6):895-904.doi:10.1111/imj.70023. pmid: 40171883
[10]	Akbayir E, Kizilay T, Erol R, et al. B-cell and T-cell populations in peripheral blood linked to ocrelizumab treatment efficacy in multiple sclerosis[J]. In Vivo, 2025, 39(2):1162-1172. doi:10.21873/invivo.13920. pmid: 40010950
[11]	Vustraxv G, Yerdfpc J, Reatic M, et al. Blood biomarkers for multiple sclerosis:Neurofilament light chain and beyond[J]. EBioMedicine, 2024, 104:105214.doi:10.1016/j.ebiom.2024.105214.
[12]	Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances[J]. Lancet Neurol, 2021, 20(6):470-483.doi:10.1016/S1474-4422(21)00063-6. pmid: 33930317
[13]	Wong JK, Lin J, Kung NJ, et al. Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic[J]. Brain, 2023, 146(5):1979-1992.doi:10.1093/brain/aawad031. pmid: 36732292
[14]	Herranz E, Treaba CA, Barletta VT, et al. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis[J]. Brain, 2024, 147(7):2566-2578.doi:10.1093/brain/awae030. pmid: 38289855
[15]	Hochstetler A, Lehtinen MK. Choroid plexus as a mediator of CNS inflammation in multiple sclerosis[J]. Mult Scler, 2024, 30(5_suppl):19-23.doi:10.1177/13524585241292974.
[16]	Wicks TR, Shalaurova I, Wolska A, et al. Endogenous ketone bodies are associated with metabolic vulnerability and disability in multiple sclerosis[J]. Nutrients, 2025, 17(4):640.doi:10.3390/nu17040640.
[17]	DeLuca J. Fatigue in multiple sclerosis: Can we measure it and can we treat it?[J]. J Neurol, 2024, 271(9):6388-6392.doi:10.1007/s00415-024-12524-9. pmid: 38967652
[18]	van Dam M, Krijnen EA, Nauta IM, et al. Identifying and understanding cognitive profiles in multiple sclerosis: A role for visuospatial memory functioning[J]. J Neurol, 2024, 271(5):2195-2206.doi:10.1007/s00415-024-12227-1. pmid: 38409536
[19]	Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study[J]. Lancet, 2018, 391(10127):1263-1273.doi: 10.1016/S0140-6736(18)30475-6. pmid: 29576505
[20]	Kapel-Reguła A, Du's-Ilnicka I, Radwan-Oczko M. Relevance of saliva analyses in terms of etiological factors, biomarkers, and indicators of disease course in patients with multiple sclerosis-A review[J]. Int J Mol Sci, 2024, 25(23):12559.doi:10.3390/ijms252312559.